Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 116

Sort by

Sort Order Select

Journal Articles

CD93 + Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

Hui Yu, Yixin Qian, Weiping Liu, Lan Mi, Yun Huang, Rui Peng, Jiaowu Cao, Dingyao Hu, Jun Zhu, Yuqin Song, Mi Deng

Blood (2024) 144 (Supplement 1): 960.

https://doi.org/10.1182/blood-2024-201309

Published: 2024

Journal Articles

Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study

Yuqin Song, Qingsong Yin, Zhiming Li, Jingye Meng, Yan Yan, Mengli Zhou, Wenyi Sun, Kezhen Liu, Jun Zhu

Blood (2024) 144 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2024-193938

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Lijuan Deng, Yanyan Liu, Ningjing Lin, Zhihua Yao, Jiuyang Zhang, Wei Meng, Qiying Lu, Wenzhi Tian, Jun Zhu, Yuqin Song

Blood (2024) 144 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2024-200539

Published: 2024

Journal Articles

Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Lijuan Deng, Tianheng He, Yongjing Tang, Lan Mi, Changyu Lu, Hanxiao Liu, Shupeng Zhong, Jin Chai, Jun Luo, Liling Zhang, Shujuan Wen, Xiaopei Wang, Jun Zhu, Yuqin Song

Blood (2024) 144 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2024-209021

Published: 2024

Journal Articles

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Ningjing Lin, Tingting Du, Hui Zhou, Yajun Li, Liang Wang, Xiaomeng Dong, Haochuan Zheng, Jingtao Lu, Mi Tang, Jihua Wu, Wei Zhu, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2024-206674

Published: 2024

Journal Articles

Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

Jie Chen, Linjun Zhao, Chongyang Wu, Haifeng Yu, Zhenling Li, Lihong Liu, Da Gao, Ying Sun, Xiaolei Wei, Yuanbin Wu, Yue Wang, Yuqin Song, Jun Zhu, Weiping Liu

Blood (2024) 144 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2024-207412

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

Weiping Liu, Yao Liu, Zengjun Li, Shujuan Wen, Zhihua Zhang, Liqun Zou, Ming Jiang, Liping Dou, Ou Bai, Jie Yu, Yue Wang, Jie Chen, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 6389.

https://doi.org/10.1182/blood-2024-199929

Published: 2024

Journal Articles

Safety and Efficacy of Iruplinalkib for Patients with Relapsed or Refractory (r/r) ALK+ Lymphoma: A Phase II Trial

Yue Wang, Fang Wei, Wanli Wang, Linjun Zhao, Jie Chen, Yuqin Song, Jun Zhu, Weiping Liu

Blood (2024) 144 (Supplement 1): 6386.

https://doi.org/10.1182/blood-2024-207002

Published: 2024

Journal Articles

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Yuqin Song, Zengjun Li, Ling Li, Zhengzi Qian, Keshu Zhou, Lei Fan, Peter Tan, Pratyush Giri, Zhiming Li, Melita Kenealy, Jie Jin, Wei Liu, Shafqat Inam, Yan Xie, Xia Guo, Wenduo He, Raymond Xu, Tong Li, Jun Zhu

Blood (2023) 142 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2023-188444

Published: 2023

Journal Articles

IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classic Hodgkin Lymphoma: An Open Label, Multicenter, Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity

Keshu Zhou, Yuqin Song, Tienan Yi, Shuling Hou, Xingchen Liu, Ningjing Lin, Tingting Du, Xing Zhao, Xiaobo Wu, Xiwen Zhao, Wei Meng, Wencheng Xu, Qiying Lu, Wenzhi Tian, Jun Zhu

Blood (2023) 142 (Supplement 1): 609.

https://doi.org/10.1182/blood-2023-174829

Published: 2023

Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Blood (2023) 142 (Supplement 1): 306.

https://doi.org/10.1182/blood-2023-180137

Published: 2023

Journal Articles

Combination of CDK4/6 Inhibitor Palbociclib and PI3K Inhibitor Idelalisib Synergistically Induces an Anti-Tumor Effect in B-Cell Lymphoma and Overcomes Ibrutinib Resistance

Dingyao Hu, Jiaowu Cao, Dedao Wang, Jiajin Wu, Lan Mi, Lingyan Ping, Ning Ding, Yuqin Song, Jun Zhu

Blood (2023) 142 (Supplement 1): 2826.

https://doi.org/10.1182/blood-2023-185912

Published: 2023

Journal Articles

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lyu, Cheng Fang, Sheng Xu, Jun Zhu

Blood (2023) 142 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2023-181352

Published: 2023

Journal Articles

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2023-173645

Published: 2023

Journal Articles

Real-World Effectiveness and Safety of Hetrombopag for Delayed Platelet Engraftment Post-Allogeneic Hematopoietic Stem Cell Transplantation

JUN Zhu, Yun Lou, Chuxian Zhao, Ying Jiang, Daolin Wei, Chun Wang, Shan Shao, Huixia Liu, Su Li

Blood (2023) 142 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2023-178605

Published: 2023

Journal Articles

TBI/Ratg-Based Conditioning for Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in 11 Cases of Chemotherapy-Resistant Advanced-Stage Peripheral T-Cell Lymphoma

JUN Zhu, Rong Xu, Chun Wang, Chuxian Zhao, Ying Jiang, Daolin Wei, Shan Shao, Huixia Liu, Su Li

Blood (2023) 142 (Supplement 1): 6981.

https://doi.org/10.1182/blood-2023-174062

Published: 2023

Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu

Blood (2023) 142 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2023-180413

Published: 2023

Journal Articles

Short-Term Substitution of Calcineurin Inhibitors (CNIs) with Recombinant Humanized Anti-CD25 Monoclonal Antibody (anti-CD25 rhMAb) As aGVHD Prophylaxis in Cnis Intolerant Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Shan Shao, Huixia Liu, Ying Jiang, Su Li, Daolin Wei, JUN Zhu, Chun Wang, Chuxian Zhao

Blood (2023) 142 (Supplement 1): 7007.

https://doi.org/10.1182/blood-2023-173673

Published: 2023

NARROW

CD93 + Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

Safety and Efficacy of Iruplinalkib for Patients with Relapsed or Refractory (r/r) ALK+ Lymphoma: A Phase II Trial

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classic Hodgkin Lymphoma: An Open Label, Multicenter, Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Combination of CDK4/6 Inhibitor Palbociclib and PI3K Inhibitor Idelalisib Synergistically Induces an Anti-Tumor Effect in B-Cell Lymphoma and Overcomes Ibrutinib Resistance

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Real-World Effectiveness and Safety of Hetrombopag for Delayed Platelet Engraftment Post-Allogeneic Hematopoietic Stem Cell Transplantation

TBI/Ratg-Based Conditioning for Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in 11 Cases of Chemotherapy-Resistant Advanced-Stage Peripheral T-Cell Lymphoma

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Short-Term Substitution of Calcineurin Inhibitors (CNIs) with Recombinant Humanized Anti-CD25 Monoclonal Antibody (anti-CD25 rhMAb) As aGVHD Prophylaxis in Cnis Intolerant Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only